Harbin Pharmaceutical shares issued a clarification announcement of the reorganization of the reform violates the commitment

NetEase Financial February 18 News Harbin Drug shares 18th evening issued a notice, denied restructuring plan violates the share reform commitment.　　February 17, 2011, there are media reports titled "Share Reform Commitment cynical HA drug shares by the main funds crazy throw" article, the article believes that Harbin Pharmaceutical shares "share reform commitment to the calculation of the return on equity should be calculated according to the evaluation value, the reorganization plan violates the reform commitment." The group had promised that the total amount of assets injected would be no less than 2.611 billion yuan, and that the asset yield of the assets in the previous fiscal year after deducting non-recurrent gains would not be less than 11% per cent.　　The media said that although the total amount of assets injected was in line with the commitment, the net asset yield of the underlying assets was difficult to reach 11% per cent of its commitments. In response to the above query, Harbin Pharmaceutical shares announced that the company's reorganization of the proposed acquisition of assets involving listed companies and state-owned assets pricing.　　According to the relevant provisions, bio-engineering companies must be evaluated on the basis of valuation, three-fine pharmaceutical as a listed company, the valuation should be "the transfer of state-owned shareholders of listed companies in the management of shares of the interim measures" (Sasac, the CSRC 19th text) as the basis, and can not be determined Harbin Pharmaceutical shares said that the three refined pharmaceutical net assets yield higher than the shares of Harbin Medicine, therefore, the Kazakh drug shares after the reorganization of the return on net assets before the reorganization of the increase (analog data). Bioengineering Company 2010 deduction of Non-recurrent gains and losses after the net assets yield of 33.35% (unaudited), also higher than the shares of Harbin Medicine, its pre-valuation corresponding to the P/E ratio is far lower than the bio-pharmaceutical companies on average P/E and Harbin Pharmaceutical shares, bio-engineering companies injected into favor of the increase in　　The valuation of Harbin Pharmaceutical shares has been enhanced to protect the interests of all shareholders of Harbin Pharmaceutical shares. Harbin Pharmaceutical shares said that the restructuring plan for all aspects of the consideration are in line with existing provisions, there is no violation of the share reform commitments.　　Judging from the reorganization cases of other listed companies, the evaluation value is only the basis of pricing, it has not been found that the calculation of the net assets yield is based on the valuation value of the acquired assets, therefore, the theory that "the rate of return on net assets should be calculated according to the evaluation value" and "breach of the share reform commitment" is not reasonable. Harbin Pharmaceutical shares 18th low open after the concussion upstream, closed down 0.04%, reported at 22.81 Yuan.